StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Editas Medicine (EDIT) PT Lowered to $8 at Truist Securities
November 4, 2024 12:25 PM
Truist Securities analyst Joon Lee lowered the price target on Editas Medicine (NASDAQ: EDIT) to $8.00 (from ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
Next Articles
Chardan Capital Markets Reiterates Buy Rating on Editas Medicine (EDIT)
November 5, 2024 4:19 PM
Editas Medicine (EDIT) PT Lowered to $5 at Barclays
November 5, 2024 5:23 AM
Raymond James Downgrades Editas Medicine (EDIT) to Market Perform
November 4, 2024 12:23 PM
Form SC 13G/A Editas Medicine, Inc. Filed by: VANGUARD GROUP INC
November 4, 2024 11:57 AM
Editas Medicine (EDIT) Reports In-Line Q3 EPS
November 4, 2024 7:45 AM
Form 10-Q Editas Medicine, Inc. For: Sep 30
November 4, 2024 7:37 AM
Form 8-K Editas Medicine, Inc. For: Nov 04
November 4, 2024 7:34 AM
Editas Medicine Announces Third Quarter 2024 Results and Business Updates
November 4, 2024 7:30 AM
